Bill Text: IA HF2140 | 2019-2020 | 88th General Assembly | Introduced
Bill Title: A bill for an act relating to patient education prior to the prescription of an opioid.
Spectrum: Partisan Bill (Republican 1-0)
Status: (Introduced - Dead) 2020-02-05 - Subcommittee recommends indefinite postponement. [HF2140 Detail]
Download: Iowa-2019-HF2140-Introduced.html
House
File
2140
-
Introduced
HOUSE
FILE
2140
BY
A.
MEYER
A
BILL
FOR
An
Act
relating
to
patient
education
prior
to
the
prescription
1
of
an
opioid.
2
BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
3
TLSB
5835YH
(3)
88
ss/rh
H.F.
2140
Section
1.
NEW
SECTION
.
124.559
Provision
of
information
——
1
prescribing
of
controlled
substances
for
acute
or
chronic
pain.
2
1.
Prior
to
issuing
an
initial
prescription
for
a
schedule
3
II
controlled
substance
or
any
other
prescription
opioid
in
a
4
course
of
treatment
for
acute
or
chronic
pain,
and
again
prior
5
to
issuing
the
third
prescription
in
the
course
of
treatment,
6
a
prescribing
practitioner
shall
discuss
with
the
patient,
7
or
the
patient’s
parent
or
guardian
if
the
patient
is
under
8
eighteen
years
of
age
and
is
not
an
emancipated
minor,
the
9
risks
associated
with
the
substance
being
prescribed,
including
10
but
not
limited
to:
11
a.
The
risks
of
addiction
and
overdose
associated
with
12
opioid
drugs
and
the
dangers
of
taking
opioid
drugs
with
13
alcohol,
benzodiazepines,
and
other
central
nervous
system
14
depressants.
15
b.
The
reasons
why
the
prescription
is
necessary.
16
c.
Alternative
treatments
that
may
be
available.
17
d.
The
risks
associated
with
the
use
of
the
substance
18
being
prescribed,
specifically
that
opioids
are
highly
19
addictive,
even
when
taken
as
prescribed,
that
there
is
a
20
risk
of
developing
a
physical
or
psychological
dependence
on
21
the
substance
and
that
the
risks
of
taking
more
opioids
than
22
prescribed,
or
mixing
sedatives,
benzodiazepines
or
alcohol
23
with
opioids,
can
result
in
fatal
respiratory
depression.
24
e.
The
dangers
and
risks
of
use
of
the
substance
to
persons
25
other
than
the
patient
using
the
substance.
The
prescribing
26
practitioner
shall
advise
the
patient
to
keep
the
substance
in
27
a
locked
container.
28
2.
The
prescribing
practitioner
shall
include
a
note
29
in
the
patient’s
medical
record
that
the
patient
or
the
30
patient’s
parent
or
guardian,
as
applicable,
has
discussed
31
with
the
practitioner
the
risks
of
developing
a
physical
or
32
psychological
dependence
on
the
prescribed
substance
and
33
alternative
treatments
that
may
be
available.
34
3.
This
section
shall
not
apply
to
a
prescription
for
the
35
-1-
LSB
5835YH
(3)
88
ss/rh
1/
3
H.F.
2140
substances
specified
for
a
patient
who
is
currently
in
active
1
treatment
for
cancer
or
receiving
hospice
or
palliative
care
2
through
a
hospice
program
as
defined
in
section
135J.1,
for
the
3
resident
of
a
long-term
care
facility,
or
to
any
substances
4
that
are
being
prescribed
for
use
in
the
treatment
of
substance
5
use
disorder
or
opioid
dependence.
6
4.
As
used
in
this
section:
7
a.
“Long-term
care
facility”
means
the
same
as
defined
in
8
section
231.4.
9
b.
“Prescribing
practitioner”
means
the
same
as
defined
in
10
section
124.550.
11
Sec.
2.
CODE
EDITOR
DIRECTIVE.
The
Code
editor
shall
12
designate
section
124.559,
as
enacted
in
this
Act,
as
a
new
13
subchapter
within
chapter
124.
14
EXPLANATION
15
The
inclusion
of
this
explanation
does
not
constitute
agreement
with
16
the
explanation’s
substance
by
the
members
of
the
general
assembly.
17
This
bill
relates
to
the
information
to
be
provided
by
a
18
prescribing
practitioner
to
a
patient
prior
to
the
prescribing
19
of
a
controlled
substance
for
acute
or
chronic
pain.
The
bill
20
provides
that
prior
to
issuing
an
initial
prescription
of
a
21
schedule
II
controlled
substance
or
any
other
prescription
22
opioid
in
a
course
of
treatment
for
acute
or
chronic
pain,
and
23
again
prior
to
issuing
the
third
prescription
in
the
course
of
24
treatment,
a
prescribing
practitioner
shall
discuss
with
the
25
patient,
or
the
patient’s
parent
or
guardian
if
the
patient
26
is
under
18
years
of
age
and
is
not
an
emancipated
minor,
the
27
risks
associated
with
the
substance
being
prescribed.
The
28
information
to
be
discussed
includes
but
is
not
limited
to:
29
the
risks
of
addiction
and
overdose
associated
with
opioid
30
drugs
and
the
dangers
of
taking
opioid
drugs
with
alcohol,
31
benzodiazepines,
and
other
central
nervous
system
depressants;
32
the
reasons
why
the
prescription
is
necessary;
alternative
33
treatments
that
may
be
available;
the
risks
associated
with
34
the
use
of
the
substance
being
prescribed;
and
the
dangers
35
-2-
LSB
5835YH
(3)
88
ss/rh
2/
3
H.F.
2140
and
risks
of
use
of
the
substance
by
persons
other
than
the
1
patient.
The
prescribing
practitioner
shall
include
a
note
2
in
the
patient’s
medical
record
that
the
patient
or
the
3
patient’s
parent
or
guardian,
as
applicable,
has
discussed
4
with
the
practitioner
the
risks
of
developing
a
physical
or
5
psychological
dependence
on
the
prescribed
substance
and
6
alternative
treatments
that
may
be
available.
The
bill
does
7
not
apply
to
a
prescription
for
the
substances
specified
in
8
the
bill
for
a
patient
who
is
currently
in
active
treatment
9
for
cancer
or
receiving
hospice
or
palliative
care
through
a
10
hospice
program,
for
the
resident
of
a
long-term
care
facility,
11
or
to
any
substances
that
are
being
prescribed
for
use
in
the
12
treatment
of
substance
use
disorder
or
opioid
dependence.
13
-3-
LSB
5835YH
(3)
88
ss/rh
3/
3
